

## Celltrion, Juno establish biosimilar partnership

18 October 2019 | News

**Covering the biosimilar products Herzuma (biosimilar trastuzumab), and Truxima (biosimilar rituximab)**



Celltrion Healthcare Australia (Celltrion) and Juno Pharmaceuticals (Juno) have entered into a co-marketing partnership, covering the biosimilar products Herzuma (biosimilar trastuzumab), and Truxima (biosimilar rituximab).

Celltrion Healthcare Australia, a division of the biosimilar developer Celltrion Healthcare, are the Marketing Authorisation holders in Australia for these and other biosimilar brands and will distribute the products in the market. Juno as a leading supplier into hospitals, has been appointed to provide sales promotion and hospital contracting services to Australian Hospital market customers.

Commenting on this partnership, Cecilia Sung – Country Manager ANZ stated that Celltrion Healthcare Australia is pleased with the opportunity to partner with Juno Pharmaceuticals to offer our global biosimilar brands to Australian Healthcare professionals and patients, with a blend of quality & economic benefits. We are also confident that with an extensive commercial network, strong customer relationships and established hospital market presence by Juno Pharmaceuticals, Biosimilar brands from Celltrion Healthcare will achieve high customer acceptance as they have been in regulated markets such as EU/ USA.

“We are excited that Celltrion has chosen Juno to represent their rituximab and trastuzumab products in Australia. The Juno team has very extensive experience with biosimilars in the Australian marketplace over the last decade” says Mark Crotty, CEO Juno Australia.